The combination of three molecular markers can be a valuable predictive tool for the prognosis of hepatocellular carcinoma patients

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Chen, Sheng Sen ^a   Yu, Kang Kang ^a   Ling, Qing Xia ^a   Huang, Chong ^a   Li, Ning ^a   Zheng, Jian Ming ^a   Bao, Su Xia ^a   Cheng, Qi ^a   Zhu, Meng Qi ^a   Chen, Ming Quan ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DUOX1 PROTEIN, HUMAN; FRUCTOSE BISPHOSPHATASE; GLS2 PROTEIN, HUMAN; GLUTAMINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; FEMALE; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; THEORETICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; FEMALE; FRUCTOSE-BISPHOSPHATASE; GLUTAMINASE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, THEORETICAL; NADPH OXIDASE; PROGNOSIS; YOUNG ADULT;

EID: 84964305168     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24582     Document Type: Article

References (42)

1. Siegel, R. et al. Cancer Statistics, 2013. CA Cancer J Clin. 63, 11-30 (2013).
2. Mittal, S. et al. Epidemiology of Hepatocellular Carcinoma: Consider the Population. J Clin Gastroenterol. 47 Suppl, S2-S6 (2013).
3. El-Serag, H. B. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology 142, 1264-1273 (2012).
4. Rapti, I. et al. Risk for Hepatocellular Carcinoma in the Course of Chronic Hepatitis B Virus Infection and the Protective Effect of Therapy with Nucleos(T)ide Analogues. World J Hepatol. 7, 1064-1073 (2015).
5. Lozano, R. et al. Global and Regional Mortality From 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010. Lancet. 380, 2095-2128 (2012).
6. Cervello, M. et al. Targeted Therapy for Hepatocellular Carcinoma: Novel Agents On the Horizon. Oncotarget 3, 236-260 (2012).
7. Maluccio, M. et al. Recent Progress in Understanding, Diagnosing, and Treating Hepatocellular Carcinoma. CA Cancer J Clin. 62, 394-399 (2012).
8. Bruix, J. et al. Hepatocellular Carcinoma: Clinical Frontiers and Perspectives. Gut. 63, 844-855 (2014).
9. Zhu, A. X. et al. HCC and Angiogenesis: Possible Targets and Future Directions. Nat Rev Clin Oncol. 8, 292-301 (2011).
10. Roy, K. et al. NADPH Oxidases and Cancer. Clinical Science 128, 863-875 (2015).
11. De Deken, X. et al. Cloning of Two Human Thyroid cDNAs Encoding New Members of the NADPH Oxidase Family. J Biol Chem. 275, 23227-23233 (2000).
12. Fischer, H. Mechanisms and Function of DUOX in Epithelia of the Lung. Antioxid Redox Signal 11, 2453-2465 (2009).
13. Mates, J. M. et al. Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer. Curr Mol Med. 13, 514-534 (2013).
14. Hu, W. et al. Glutaminase 2, a Novel P53 Target Gene Regulating Energy Metabolism and Antioxidant Function. Proc Natl Acad Sci USA 107, 7455-7460 (2010).
15. Suzuki, S. et al. Phosphate-Activated Glutaminase (GLS2), a P53-Inducible Regulator of Glutamine Metabolism and Reactive Oxygen Species. Proc Natl Acad Sci USA 107, 7461-7466 (2010).
16. Dong, C. et al. Loss of FBP1 by Snail-mediated Repression Provides Metabolic Advantages in Basal-Like Breast Cancer. Cancer Cell 23, 316-331 (2013).
17. Chen, M. et al. Promoter Hypermethylation Mediated Downregulation of FBP1 in Human Hepatocellular Carcinoma and Colon Cancer. PLoS One 6, e25564 (2011).
18. Zhang, J. et al. Epigenetic Silencing of Glutaminase 2 in Human Liver and Colon Cancers. BMC Cancer 13, 601 (2013).
19. Ling, Q. et al. Epigenetic Silencing of Dual Oxidase 1 by Promoter Hypermethylation in Human Hepatocellular Carcinoma. Am J Cancer Res. 4, 508-517 (2014).
20. Tong, L. et al. Reactive Oxygen Species in Redox Cancer Therapy. Cancer Lett. 367, 18-25 (2015).
21. Sablina, A. A. et al. The Antioxidant Function of the P53 Tumor Suppressor. Nat Med. 11, 1306-1313 (2005).
22. D'Autreaux, B. et al. ROS as Signalling Molecules: Mechanisms that Generate Specificity in ROS Homeostasis. Nat Rev Mol Cell Biol. 8, 813-824 (2007).
23. Cabello, C. M. et al. Experimental Therapeutics: Targeting the Redox Achilles Heel of Cancer. Curr Opin Investig Drugs 8, 1022-1037 (2007).
24. Fruehauf, J. P. et al. Reactive Oxygen Species: A Breath of Life Or Death? Clin Cancer Res. 13, 789-794 (2007).
25. Nagasue, N. et al. Liver Resection for Hepatocellular Carcinoma. Results of 229 Consecutive Patients During 11 Years. Ann Surg. 217, 375-384 (1993).
26. Edge, S. B. et al. The American Joint Committee on Cancer: The 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Annals of Surgical Oncology 17, 1471-1474 (2010).
27. Eisenhauer, E. A. et al. New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). Eur J Cancer 45, 228-247 (2009).
28. Livak, K. J. et al. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408 (2001).
29. Taravat, A. et al. Adaptive Weibull Multiplicative Model and Multilayer Perceptron Neural Networks for Dark-Spot Detection From SAR Imagery. Sensors (Basel) 14, 22798-22810 (2014).
30. Paschalidou, A. K. et al. Forecasting Hourly PM(10) Concentration in Cyprus through Artificial Neural Networks and Multiple Regression Models: Implications to Local Environmental Management. Environ Sci Pollut Res Int. 18, 316-327 (2011).
31. Dharmasaroja, P. et al. Prediction of Intracerebral Hemorrhage Following Thrombolytic Therapy for Acute Ischemic Stroke Using Multiple Artificial Neural Networks. Neurol Res. 34, 120-128 (2012).
32. Gokcan, H. et al. Predictors of Survival in Hepatocellular Carcinoma Patients. Ann Transplant 20, 596-603 (2015).
33. Hwang, S. et al. The Impact of Tumor Size on Long-Term Survival Outcomes After Resection of Solitary Hepatocellular Carcinoma: Single-Institution Experience with 2558 Patients. J Gastrointest Surg. 19, 1281-1290 (2015).
34. Carr, B. I. et al. Low Alpha-Fetoprotein Levels are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis. Digestive Diseases and Sciences doi: 10.1007/s10620-015-3922-3 (2015).
35. Hahn, W. C. et al. Rules for Making Human Tumor Cells. N Engl J Med. 347, 1593-1603 (2002).
36. Taylor, W. R. et al. Regulation of the G2/M Transition by P53. Oncogene 20, 1803-1815 (2001).
37. Bhattacharyya, S. et al. Tumour, Oxidative Stress and Host T Cell Response: Cementing the Dominance. Scand J Immunol. 82, 477-488 (2015).
38. Ramsey, M. R. et al. ROS as a Tumour Suppressor? Nat Cell Biol. 8, 1213-1215 (2006).
39. Kao, W. et al. Prognosis of Early-Stage Hepatocellular Carcinoma. Medicine 94, e1929 (2015).
40. Zhou, N. et al. Low-Level Expression of microRNA-375 Predicts Poor Prognosis in Hepatocellular Carcinoma. Tumor Biology, doi: 10.1007/s13277-015-3841-0 (2015).
41. Ferlay, J. et al. Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. Int J Cancer 127, 2893-2917 (2010).
42. Starley, B. Q. et al. Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection. Hepatology 51, 1820-1832 (2010).